|
1. Shawler, D. L., R. M. Bartholomew, L. M. Smith, and R. O. Dillman. 1985. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135: 1530-1535. 2. Balls, M., A. M. Goldberg, J. H. Fentem, C. L. Broadhead, R. L. Burch, M. F. Festing, J. M. Frazier, C. F. Hendriksen, M. Jennings, M. D. yan der Kamp, D. B. Morton, A. N. Rowan, C. Russell, W. M. Russell, H. Spielmann, M. L. Stephens, W. S. Stokes, D. W. Straughan, J. D. Yager, J. Zurol, and B. F. van Zutphen. 1995. The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. Altern Lab Anim. 23: 838-866. 3. Junghans, R. P., T. A. Waldmann, N. F. Landolfi, N. M. Avdalovic, W. P. Schneider, and C. Queen. 1990. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50:1495-1502. 4. Vaughan, T. J., J. K. Osbourn, and P. R. Tempest. 1998. Human antibodies by design. Nat Biotechnol. 16: 535-539. 5. Lobuglio, A. F., R. H. Wheeler, J. Trang, A. Hayens, K. Rogers, E. B. Harvey, L. Sun, J. Ghrayeb, and M. B. Khazaeli. 1989. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA. 86: 4220-4224. 6. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet. 344: 1105-1110. 7. Jones, P. T., P. H. Dear, J. Foote, M. S. Neuberger, and G. Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321: 522 -525. 8. Foote, J., and G. Winter. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224: 487-499. 9. Mclaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, V. Jain, A. D. Ho, J. Lister, K. Wey, D. Shen, and B. K. Dallarie. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833. 10. Pegram, M. D., A. Lipton, D. F. Hayes, B. L. Weber, J. M. Baselga, D. Tripathy, D. Baly, S. A. Baughman, T. Twaddell, J. A. Glaspy, and D. J. Slamon. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16: 2659-2671. 11. Vincenti, F., B. Nashan, and S. Light. 1998. Daclizumab: outcome of phase III trials and mechanism of action. Transplant. Proc. 30: 2155-2158. 12. Bruggemann, M., and M. S. Neuberger. 1996. Strategies for expressing human antibody repertoires in transgenic mice. Immunol. Today. 17: 391-397. 13. Winter, G., A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12: 433-455. 14. Gavilondo, J. V., and J. W. Larrick. 2000. Antibody engineering at the millennium. Biotechniques. 128 -132, 134-136, 138 passim. 15. Smothers, J. F., S. Henikoff, and P. Carter. 2002. Affinity selection from biological libraries. Science. 298: 621-622. 16. Tan, W. S., G. H. Tan, K. Yusoff, and H. F. Seow. 2005. A phage-displayed cyclic peptide that interacts tightly with the immunodominant region of hepatitis B surface antigen. J. Clin. Virol. 34: 35-41. 17. Pasqualini, R., and E. Ruoslahti.1996. Organ targeting in vivo using phage display peptide libraries. Nature. 380: 364-366. 18. Laakkonen, P., K. Porkka, J. A. Hoffman, and E. Ruoslahti. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8: 751-755. 19. Odermatt, A., A. Audige, C. Frick, B. Vogt, B. M. Frey, F. J. Frey, and L. Mazzucchelli. 2001. Identification of receptor ligands by screening phage-display peptide libraries ex vivo on microdissected kidney tubules. J. Am. Soc. Nephrol. 12: 308-316. 20. Wang, B., Y. B. Chen, O. Ayalon, J. Bender, and A. Garen. 1999. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proc. Natl. Acad. Sci. USA. 96: 1627-1632. 21. Melani, C., M. Figini, D. Nicosia, E. Luison, V. Ramakrishna, G. Casorati, G. Parmiani, Z. Eshhar, S. Canevari, and M. P. Colombo. 1998. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58: 4146-4154. 22. Marks, J. D., H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222: 581-597. 23. Sui, J., Y. He, X. Jiang, S. Dubel, Z. Han, and Z. Song. 2004. A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Hum Antibodies. 13: 111-118. 24. Lehmann, J. M., B. Holzmann, E. W. Breitbart, P. Schmiegelow, G. Riethmüller, and J. P. Johnson. 1987. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 47: 841-845. 25. Shih, I. M., T. L. Wang, and W. H. Westra. 1996. Diagnostic and biological implications of Mel-CAM expression in mesenchymal neoplasms. Clin Cancer Res. 2: 569-575. 26. Lehmann, J. M., G. Riethmüller, and J. P. Johnson.1989. MUC-18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA. 86: 9891-9895. 27. Pourquie, O., C. Corbel, J. L. Caer, J. Rossier, and N. M. Le Douarin. 1992. BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc. Natl. Acad. Sci. USA. 89: 5261-5265. 28. Cunningham, B. A., J. J. Hemperly, B. A. Murray, E. A. Prediger, R. Brackenbury, and G. M. Edelman. 1987. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science. 236: 799-806. 29. Fearon, E. R., K. R. Cho, J. M. Nigro, S. E. Kern, J. W. Simons, J. M. Ruppert, S. R. Hamilton, A. C. Preisinger, G. Thomas, K. W. Kinzler, and B. Vogelstein. 1990. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 247: 49-56. 30. Shih, I. M. 1999. The role of CD146 (Mel-CAM) in biology and pathology. J. Pathol. 189: 4-11. 31. Bardin, N., V. Francès, G. Lesaule, N. Horschowski, F. George, and J. Sampol. 1996. Identification of the S-Endo 1 endothelial-associated antigen. Biochem. Biophys. Res. Commun. 218: 210-216. 32. Sers, C., K. Kirsch, U. Rothbacher, G. Riethmüller, and J. P. Johnson. 1993. Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc. Natl. Acad. Sci. USA. 90: 8514-8518. 33. Pickl, W. F., O. Majdic, G. F. Fischer, P. Petzelbauer, I. Fae, M. Waclavicek, J. Stockl, C. Scheinecker, T. Vidicki, H. Aschauer, J. P. Johnson, and W. Knapp. 1997. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J. Immunol. 158: 2107-2115. 34. Johnson, J. P. 1994-1995. Identification of molecules associated with the development of metastasis in human malignant melanoma. Invasion Metastasis. 14: 123-130. 35. Shih, I. M., M. Nesbit, M. Herlyn, and R. J. Kurman. 1998. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod. Pathol. 11: 1098-1106. 36. Kieff, E, and A. B. Rickinson. 2001. Epstein-Barr virus and its replication. Fields Virology, Fourth Edition. DM Knipe and PM Howley (eds.) Lippincott Williams and Wilkins. Philadelphia, Pennsylvania. 2511-2573. 37. Cahir-McFarland, E. D., D. M. Davidson, S. L. Schauer, J. Duong, and E. Kieff. 2000. NF- B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 97: 6055-6060. 38. Yates, J., N. Warren, D. Reisman, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA. 81: 3806–3810. 39. Reisman, D., J. Yates, and B. Sugden. 1985. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol. 5: 1822–1832. 40. Chen, M. R., J. M. Middeldorp, and S. Diane Hayward. 1993. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization of subdomains of novel structure. J. Virol. 67: 4875–4885. 41. Ambinder, R. F., M. Mullen, Y. N. Chang, G. S. Hayward, and S. Diane Hayward. 1991. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J. Virol. 65: 1466-1478. 42. Frappier, L., and M. O’Donnell. 1994. Epstein-Barr nuclear antigen 1 mediates a DNA loop within the latent replication origin of Epstein-Barr virus. Proc. Natl. Acad. Sci. USA. 88: 10875-10879. 43. Snudden, D. K., J. Hearing, P. R. Smith, F. A. Grässer, and B. E. Griffin. 1994. EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins. EMBO J. 13: 4840- 4847. 44. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein- Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94: 12616–12621. 45. Wrightham, M. N., J. P. Stewart, N. J. Janjua, S. D. V. Pepper, C. Sample, C. M. Rooney, and J. R. Arrand. 1995. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology. 208: 521-530. 46. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein -Barr virus nuclear antigen-1. Nature. 375: 685-688. 47. Brinkmann, U., L. H. Pai, D. J. Fitzgerald, M. Willingham, and I. Pastan. 1991. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA. 88: 8616-8620. 48. Milenic, D. E., T. Yokota, D. R. Filpula, M. A. Finkelman, S. W. Dodd, J. F. Wood, M. Whitlow, P. Snoy, J. Schlom. 1991. Construction, binding properties, metabolism, and tumor targeting of a single- chain Fv derived from the pancarcinoma monoclonal antibody CC19. Cancer Res. 51: 6363-6371. 49. Yokota, T., D. E. Milenic, M. Whitlow, J. Schlom. 1992. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52: 3402-3408. 50. Griffiths, A. D., S. C. Williams, O. Hartley, lan M. Tomlinson, P. Waterhouse, W. L. Crosby, R. E. Kontermann, P. T. Jones, N. M. Low, T. John Allison, T. D. Prospero, H. R. Hoogenboom, A. Nissim, J. P. L. Cox, J. L. Harrison, M. Zaccolo, E. Gherardi, and G. Winter. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13: 3245-3260. 51. Chen, M. R., J. F. Yang, T. Y. Hsu, M. Y. Liu, J. Y. Chen, C. S. Yang. 1996. Use of bacterially expressed GST/EBNA-1 fusion proteins for detection of antibodies in sera from patients with nasopharyngeal carcinoma and healthy donors. Chinese journal of microbiology and immunology. 29: 65-79. 52. Liao, S. K., Y. P. Perng, Y. C. Shen, P. J. Chung, Y. S. Chang, and C. H. Wang. 1998. Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPC-BM1) derived from a bone marrow metastatic lesion. Cancer Genet Cytogenet. 103: 52-58. 53. Menezes, J., W. Leibold, G. Klein, G. Clements. 1975. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV- genome-negative African Burkitt’s lymphoma. Biomedicine. 22: 276-284. 54. Vaughan, T. J., A. J. Williams, K. P. Jane, K. Osbourn, A. R. Pope, J. C. Earnshaw, J. McCafferty, R. A. Hodits, J. Wilton, and K. S. Johnson. 1996 Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 14: 309-314. 55. Margaret Merchant, A., Z. Zhu, J. Q. Yuan, A. Goddard, C. W. Adams, L. G. Presta, and P. Carter. 1998. An efficient route to human bispecific IgG. Nat Biotechnol. 16: 677-681. 56. Nissim, A., H. R. Hoogenboom, I. M. Tomlinson, G. F. Carol Midgley, D. Lane, and G. Winter. 1994. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13: 692-698. 57. Griffiths, A. D., M. Malmqvist, J. D. Marks, J. M. Bye, M. J. Embleton, J. McCafferty, M. Baier, K. Philipp Holliger, B. D. Gorick, N. C. Hughes-Jones, H. R. Hoogenboom, and G. Winter. 1993. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12: 725-734. 58. Yokota, T., D. E. Milenic, M. Whitlow, and J. Schlom. 1992. Rapid tumor penetration of a single- chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52: 3402-3408. 59. Marks, C., and J. D. Marks. 1996. Phage libraries-a new route to clinically useful antibodies. N Engl J Med. 335: 730-733. 60. Schier, R., J. D. Marks, E. J. Wolf, G. Apell, C. Wong, J. E. McCartney, M. A. Bookman, J. S. Huston, L. L. Houston, L. M. Weiner, et al. 1995. In vitro and in vivo characterization of a human anti-c-erbB -2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1: 73-81.
|